Long-Term Ketamine Self-Injections in Major Depressive Disorder: Focus on Tolerance in Ketamine’s Antidepressant Response and the Development of Ketamine Addiction

Journal of Psychoactive Drugs

Volumn 47, Issue 4, 2015, Pages 276-285

  Bonnet, Udo ^a,b  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

addiction; alcohol; antidepressant effect; ketamine; tolerance

Indexed keywords

KETAMINE; VENLAFAXINE; ANTIDEPRESSANT AGENT;

ADULT; AMNESIA; ANTIDEPRESSANT ACTIVITY; ARTICLE; CASE REPORT; CONSCIOUSNESS DISORDER; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG BIOAVAILABILITY; DRUG DEPENDENCE; DRUG TOLERANCE; FEMALE; FOLLOW UP; HAMILTON DEPRESSION RATING SCALE; HUMAN; MAJOR DEPRESSION; MIDDLE AGED; TREATMENT OUTCOME; ADDICTION; DEPRESSIVE DISORDER, MAJOR; DRUG SELF ADMINISTRATION; INTRAMUSCULAR DRUG ADMINISTRATION;

ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; DRUG TOLERANCE; FEMALE; HUMANS; INJECTIONS, INTRAMUSCULAR; KETAMINE; MIDDLE AGED; SELF ADMINISTRATION; SUBSTANCE-RELATED DISORDERS;

EID: 84944351815     PISSN: 02791072     EISSN: 21599777     Source Type: Journal    
DOI: 10.1080/02791072.2015.1072653     Document Type: Article

References (78)

1. TM. Washington, DC: American Psychiatric Publishing.
2. A.E.Autry,, M.Adachi, E.Nosyreva, E.S.Na, M.F.Los, P.-F.Cheng, E.T.Kavalali, and L.M.Monteggia. 2011. NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature 475 (7354):91–95. doi:10.1038/nature10130.
3. R.M.Berman,, A.Cappiello, A.Anand, D.A.Oren, G.R.Heninger, D.S.Charney, and J.H.Krystal. 2000. Antidepressant effects of ketamine in depressed patients. Biological Psychiatry 47 (4):351–54. doi:10.1016/S0006-3223(99)00230-9.
4. P.Blier,, D.Zigman, and J.Blier. 2012. On the safety and benefits of repeated intravenous injections of ketamine for depression. Biological Psychiatry 72 (4):e11–2. doi:10.1016/j.biopsych.2012.02.039.
5. J.M.Boden,, and D.M.Fergusson. 2011. Alcohol and depression. Addiction 106 (5):906–14. doi:10.1111/add.2011.106.issue-5.
6. G.Bokor,, and P.D.Anderson. 2014. Ketamine: An update on its abuse. Journal of Pharmacy Practice 27 (6):582–86. doi:10.1177/0897190014525754.
7. U.Bonnet,, and N.Scherbaum. 2015. Striking similarities between clinical and biological properties of ketamine and ethanol. Linking antidepressant after effect and burgeoning addiction? J Alcohol Drug Depend 3:2. doi:10.4172/23296488.1000198.
8. E.P.Carpenter-Hyland,, and J.Chandler. 2007. Adaptive plasticity of NMDA receptors and dendritic spines: Implications for enhanced vulnerability of the adolescent brain to alcohol addiction. Pharmacology Biochemistry and Behavior 86:200–08. doi:10.1016/j.pbb.2007.01.016.
9. H.Chilukuri,, N.P.Reddy, R.M.Pathapati, A.N.Manu, S.Jollu, and A.B.Shaik. 2014. Acute antidepressant effects of intramuscular versus intravenous ketamine. Indian Journal of Psychological Medicine 36 (1):71–76. doi:10.4103/0253-7176.127258.
10. U.Chilukuri,, D.Padmavathy, and S.S.Jakka. 2013. Intramuscular ketamine in acute depression: A report on two cases. Indian Journal of Psychiatry 55 (2):186–88. doi:10.4103/0019-5545.111461.
11. 13C]-nuclear magnetic resonance spectroscopy measures of ketamine’s effect on amino acid neurotransmitter metabolism. Biological Psychiatry 71 (11):1022–25. doi:10.1016/j.biopsych.2011.11.006.
12. Cooper, J., and World Health Organization (WHO). 1994. Pocket guide to ICD-10 classification of mental and behavioral disorders with glossary and diagnostic criteria for research ICD-10: CDR-10. Geneva, Switzerland: WHO.
13. M.Cooper,, M.Russell, J.B.Skinner, and M.Windle. 1992. Development and validation of a three-dimensional measure of drinking motives. Psychological Assessment 4:123–32. doi:10.1037/1040-3590.4.2.123.
14. C.Cusin,, G.Q.Hilton, A.A.Nierenberg, and M.Fava. 2012. Long-term maintenance with intramuscular ketamine for treatment-resistant bipolar II depression. American Journal of Psychiatry 169 (8):868–69. doi:10.1176/appi.ajp.2012.12020219.
15. V.A.de Silva,, and R.Hanwella. 2012. Efficacy and tolerability of venlafaxine versus specific serotonin reuptake inhibitors in treatment of major depressive disorder: A meta-analysis of published studies. International Clinical Psychopharmacology 27 (1):8–16. doi:10.1097/YIC.0b013e32834ce13f.
16. R.S.Duman,, N.Li, R.-J.Liu, V.Duric, and G.Aghajanian. 2012. Signaling pathways underlying the rapid antidepressant actions of ketamine. Neuropharmacology 62 (1):35–41. doi:10.1016/j.neuropharm.2011.08.044.
17. G.A.Fava,, and E.Offidani. 2011. The mechanisms of tolerance in antidepressant action. Progress in Neuro-Psychopharmacology and Biological Psychiatry 35 (7):1593–602. doi:10.1016/j.pnpbp.2010.07.026.
18. M.F.Folstein,, S.E.Folstein, and P.R.McHugh. 1975. “Mini-Mental State”: A practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research 12:189–98. doi:10.1016/0022-3956(75)90026-6.
19. G.Fond,, A.Loundou, C.Rabu, A.Macgregor, C.Lançon, M.Brittner, J.-A.Micoulaud-Franchi, R.Richieri, P.Courtet, M.Abbar, M.Roger, M.Leboyer, and L.Boyer. 2014. Ketamine administration in depressive disorders: A systematic review and meta-analysis. Psychopharmacology (Berl) 231 (18):3663–76. doi:10.1007/s00213-014-3664-5.
20. P.Glue,, A.Gulati, and S.Duffull. 2011. Dose- and exposure-response to ketamine in depression. Biological Psychiatry 70 (4):e9–10. doi:10.1016/j.biopsych.2010.11.031
21. S.Goyal,, A.Ambekar, and R.Ray. 2014. Ketamine dependence in an anesthesiologist: An occupational hazard? Indian Journal of Psychological Medicine 36 (3):335–37. doi:10.4103/0253-7176.135395.
22. Hamilton Depression Rating Scale (HAMD)—Instructions for the Clinician. 2015. http://imaging.ubmmedica.com/all/editorial/psychiatrictimes/pdfs/clinical-scales-ham-d-instructions.pdf (accessed January 15, 2015).
23. M.Hamilton, 1960. A rating scale for depression. Journal of Neurology, Neurosurgery & Psychiatry 23:56–62. doi:10.1136/jnnp.23.1.56.
24. C.Harihar,, P.Dasari, and J.S.Srinivas. 2013. Intramuscular ketamine in acute depression: A report on two cases. Indian Journal of Psychiatry 55 (2):186–88. doi:10.4103/0019-5545.111461.
25. S.A.Irwin,, A.Iglewicz, R.A.Nelesen, J.Y.Lo, C.H.Carr, S.D.Romero, and L.S.Lloyd. 2013. Daily oral ketamine for the treatment of depression and anxiety in patients receiving hospice care: A 28-day open-label proof-of-concept trial. Journal of Palliative Medicine 16 (8):958–65. doi:10.1089/jpm.2012.0617.
26. Y.Izumi,, and C.F.Zorumski. 2014. Metaplastic effects of subanesthetic ketamine on CA1 hippocampal function. Neuropharmacology 86:273–81. doi:10.1016/j.neuropharm.2014.08.002.
27. K.L.Jansen, 2000. A review of the nonmedical use of ketamine: Use, users and consequences. Journal of Psychoactive Drugs 32 (4):419–33. doi:10.1080/02791072.2000.10400244.
28. K.L.Jansen,, and R.Darracot-Cankovic. 2001. The nonmedical use of ketamlne, part two: A review of problem use and dependence. Journal of Psychoactive Drugs 33 (2):151–58. doi:10.1080/02791072.2001.10400480.
29. S.S.Kalsi,, D.M.Wood, and P.I.Dargan. 2011. The epidemiology and patterns of acute and chronic toxicity associated with recreational ketamine use. Emerging Health Threats Journal 4:7107.
30. N.Katalinic,, R.Lai, A.Somogyi, P.B.Mitchell, P.Glue, and C.K.Loo. 2013. Ketamine as a new treatment for depression: A review of its efficacy and adverse effects. Australian & New Zealand Journal of Psychiatry 47 (8):710–27. doi:10.1177/0004867413486842.
31. E.T.Kavalali,, and L.M.Monteggia. 2012. Synaptic mechanisms underlying rapid antidepressant action of ketamine. American Journal of Psychiatry 169 (11):1150–56. doi:10.1176/appi.ajp.2012.12040531.
32. X.Ke,, Y.Ding, K.Xu, H.He, M.Zhang, D.Wang, X.Deng, X.Zhang, C.Zhou, Y.Liu, Y.Ning, and N.Fan. 2014. Serum brain-derived neurotrophic factor and nerve growth factor decreased in chronic ketamine abusers. Drug and Alcohol Dependence 142:290–94. doi:10.1016/j.drugalcdep.2014.06.043.
33. J.H.Krystal,, S.Madonick, E.Perry, R.Gueorguieva, L.Brush, Y.Wray, A.Belger, and D.C.D’Souza. 2006. Potentiation of low dose ketamine effects by naltrexone: Potential implications for the pharmacotherapy of alcoholism. Neuropsychopharmacology 31 (8):1793–800. doi:10.1038/sj.npp.1300994.
34. R.Lai,, N.Katalinic, P.Glue, A.A.Somogyi, P.B.Mitchell, J.Leyden, S.Harper, and C.K.Loo. 2014. Pilot dose-response trial of I.V. ketamine in treatment-resistant depression. World J Biol Psychiatry 15 (7):579–84. doi:10.3109/15622975.2014.922697.
35. K.A.Lapidus,, C.F.Levitch, A.M.Perez, J.W.Brallier, M.K.Parides, L.Soleimani, A.Feder, D.V.Iosifescu, D.S.Charney, and J.W.Murrough. 2014. A randomized controlled trial of intranasal ketamine in major depressive disorder. Biological Psychiatry 76 (12):970–76. doi:10.1016/j.biopsych.2014.03.026.
36. D.R.Lara,, L.W.Bisol, and L.R.Munari. 2013. Antidepressant, mood stabilizing and procognitive effects of very low dose sublingual ketamine in refractory unipolar and bipolar depression. The International Journal of Neuropsychopharmacology 16 (9):2111–17. doi:10.1017/S1461145713000485.
37. G.L.Larkin,, and A.L.Beautrais. 2011. A preliminary naturalistic study of low-dose ketamine for depression and suicide ideation in the emergency department. The International Journal of Neuropsychopharmacology 14 (8):1127–31. doi:10.1017/S1461145711000629.
38. N.Li,, B.Lee, R.-J.Liu, M.Banasr, J.M.Dwyer, M.Iwata, X.-Y.Li, G.Aghajanian, and R.S.Duman. 2010. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 329 (5994):959–64. doi:10.1126/science.1190287.
39. M.Liebrenz,, R.Stohler, and A.Borgeat. 2009. Repeated intravenous ketamine therapy in a patient with treatment-resistant major depression. World Journal Biologic Psychiatry 10 (4–2):640–43. doi:10.1080/15622970701420481.
40. N.Lindefors,, S.Barati, and W.T.O’Connor. 1997. Differential effects of single and repeated ketamine administration on dopamine, serotonin and GABA transmission in rat medial prefrontal cortex. Brain Research 759:205–12. doi:10.1016/S0006-8993(97)00255-2.
41. M.L.Logrip,, P.H.Janak, and D.Ron. 2009. Escalating ethanol intake is associated with altered corticostriatal BDNF expression. Journal of Neurochemistry 109 (5):1459–68. doi:10.1111/jnc.2009.109.issue-5.
42. S.Marland,, J.Ellerton, G.Andolfatto, G.Strapazzon, O.Thomassen, B.Brandner, A.Weatherall, and P.Paal. 2013. Ketamine: Use in anesthesia. CNS Neurosci Ther 19 (6):381–89. doi:10.1111/cns.2013.19.issue-6.
43. V.N.Marty,, and I.Spigelman. 2012. Long-lasting alterations in membrane properties, K+ currents, and glutamatergic synaptic currents of nucleus accumbens medium spiny neurons in a rat model of alcohol dependence. Front Neurosci 6:86. doi:10.3389/fnins.2012.00086.
44. G.Mion,, and T.Villevieille. 2013. Ketamine pharmacology: An update (pharmacodynamics and molecular aspects, recent findings). CNS Neurosci Ther 19 (6):370–80. doi:10.1111/cns.2013.19.issue-6.
45. B.Moghaddam,, B.Adams, A.Verma, and D.Daly. 1997. Activation of glutamatergic neurotransmission by ketamine: A novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience 17:2921–27.
46. C.J.Morgan,, and H.V.Curran. 2012. Ketamine use: A review. Addiction 107 (1):27–38. doi:10.1111/j.1360-0443.2011.03576.x.
47. M.Y.Morgan, 1995. The management of alcohol withdrawal using chlormethiazole. Alcohol Alcohol 30 (6):771–74.
48. J.W.Murrough,, A.M.Perez, S.Pillemer, J.Stern, M.K.Parides, M.aan het rot, K.A.Collins, S.J.Mathew, D.S.Charney, and D.V.Iosifescu. 2013. Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biological Psychiatry 74 (4):250–56. doi:10.1016/j.biopsych.2012.06.022.
49. Z.Nasreddine, 2015. The Montreal Cognitive Assessment (MOCA). http://www.mocatest.org/pdf_files/test/MOCA-Test-German2.pdf (accessed January 15, 2015).
50. M.Naughton,, G.Clarke, O.F.O′Leary, J.F.Cryan, and T.G.Dinan. 2014. A review of ketamine in affective disorders: Current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action. Journal of Affective Disorders 156:24–35. doi:10.1016/j.jad.2013.11.014.
51. J.Neasta,, S.Barak, S.B.Hamida, and D.Ron. 2014. mTOR complex 1: A key player in neuroadaptations induced by drugs of abuse. Journal of Neurochemistry 130 (2):172–84. doi:10.1111/jnc.2014.130.issue-2.
52. A.A.Nierenberg,, and L.M.DeCecco. 2001. Definitions of antidepressant treatment response, remission, nonresponse, partial response, and other relevant outcomes: A focus on treatment-resistant depression. The Journal of Clinical Psychiatry 62 (Suppl 16):5–9.
53. H.R.Pal,, N.Berry, R.Kumar, and R.Ray. 2002. Ketamine dependence. Anaesth Intensive Care 30 (3):382–84.
54. J.Persson, 2013. Ketamine in pain management. CNS Neurosci Ther 19 (6):396–402. doi:10.1111/cns.2013.19.issue-6.
55. R.B.Price,, D.V.Iosifescu, J.W.Murrough, L.C.Chang, R.K.Al Jurdi, S.Z.Iqbal, L.Soleimani, D.S.Charney, A.L.Foulkes, and S.J.Mathew. 2014. Effects of ketamine on explicit and implicit suicidal cognition: A randomized controlled trial in treatment-resistant depression. Depress Anxiety 31 (4):335–43. doi:10.1002/da.2014.31.issue-4
56. G.C.Quintero, 2013. Role of nucleus accumbens glutamatergic plasticity in drug addiction. Neuropsychiatr Dis Treat 9:1499–512.
57. K.G.Rasmussen,, T.W.Lineberry, C.W.Galardy, S.Kung, M.I.Lapid, B.A.Palmer, M.J.Ritter, K.M.Schak, C.L.Sola, A.J.Hanson, and M.A.Frye. 2013. Serial infusions of low-dose ketamine for major depression. Journal of Psychopharmacology 27 (5):444–50. doi:10.1177/0269881113478283.
58. P.O.Ribeiro,, Â.R.Tomé, H.B.Silva, R.A.Cunha, and L.M.Antunes. 2014. Clinically relevant concentrations of ketamine mainly affect long-term potentiation rather than basal excitatory synaptic transmission and do not change paired-pulse facilitation in mouse hippocampal slices. Brain Research 1560:10–17. doi:10.1016/j.brainres.2014.03.004.
59. C.I.Rodriguez,, L.S.Kegeles, A.Levinson, T.Feng, S.M.Marcus, D.Vermes, P.Flood, and H.B.Simpson. 2013. Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: Proof-of-concept. Neuropsychopharmacology 38 (12):2475–83. doi:10.1038/npp.2013.150.
60. E.J.Rose,, E.Simonotto, and K.P.Ebmeier. 2006. Limbic over-activity in depression during preserved performance on the n-back task. Neuroimage 29 (1):203–15. doi:10.1016/j.neuroimage.2005.07.002.
61. V.Sabino,, A.R.Narayan, T.Zeric, L.Steardo, and P.Cottone. 2013. mTOR activation is required for the anti-alcohol effect of ketamine, but not memantine, in alcohol-preferring rats. Behavioural Brain Research 247:9–16. doi:10.1016/j.bbr.2013.02.030.
62. F.Schifano,, J.Corkery, A.Oyefeso, T.Tonia, and A.H.Ghodse. 2008. Trapped in the “K-hole”: Overview of deaths associated with ketamine misuse in the UK (1993-2006). Journal of Clinical Psychopharmacology 28 (1):114–16. doi:10.1097/JCP.0b013e3181612cdc.
63. M.Shannon, 1998. Recent ketamine administration can produce a urine toxic screen which is falsely positive for phencyclidine. Pediatr Emerg Care 4 (2):180. doi:10.1097/00006565-199804000-00023.
64. B.B.K.Shenoda, 2014. The potential role of endogenous opioid system in the antidepressant effect of ketamine. Research in Neurology: An International Journal 2014: 733320. doi:10.5171/2014.733320.
65. P.R.Shiroma,, B.Johns, M.Kuskowski, J.Wels, P.Thuras, C.S.Albott, and K.O.Lim. 2014. Augmentation of response and remission to serial intravenous subanesthetic ketamine in treatment resistant depression. Journal of Affective Disorders 155:123–29. doi:10.1016/j.jad.2013.10.036.
66. J.Sleigh,, M.Harvey, L.Voss, and B.Denny. 2014. Ketamine: More mechanisms of action than just NMDA blockade. Trends in Anaesthesia and Critical Care 4:76–81. doi:10.1016/j.tacc.2014.03.002.
67. L.E.Sullivan,, D.A.Fiellin, and P.G.O’Connor. 2005. The prevalence and impact of alcohol problems in major depression: A systematic review. The American Journal of Medicine 118 (4):330–41. doi:10.1016/j.amjmed.2005.01.007.
68. S.M.Szymkowicz,, N.Finnegan, and R.M.Dale. 2013. A 12-month naturalistic observation of three patients receiving repeat intravenous ketamine infusions for their treatment-resistant depression. Journal of Affective Disorders 147 (1–3):416–20. doi:10.1016/j.jad.2012.10.015.
69. B.Tabakoff,, and P.L.Hoffman. 2013. The neurobiology of alcohol consumption and alcoholism: An integrative history. Pharmacology Biochemistry and Behavior 113:20–37. doi:10.1016/j.pbb.2013.10.009.
70. W.K.Tang,, H.J.Liang, C.G.Lau, A.Tang, and G.S.Ungvari. 2013. Relationship between cognitive impairment and depressive symptoms in current ketamine users. Journal of Studies on Alcohol and Drugs 74 (3):460–68. doi:10.15288/jsad.2013.74.460.
71. R.G.Thakurta,, R.Das, A.K.Bhattacharya, D.Saha, S.Sen, O.P.Singh, and B.Bisui. 2012. Rapid response with ketamine on suicidal cognition in resistant depression. Indian Journal of Psychological Medicine 34 (2):170–75. doi:10.4103/0253-7176.101793.
72. K.A.Trujillo,, M.L.Smith, B.Sullivan, C.Y.Heller, C.Garcia, and M.Bates. 2011. The neurobehavioral pharmacology of ketamine: Implications for drug abuse, addiction, and psychiatric disorders. ILAR Journal 52 (3):366–78. doi:10.1093/ilar.52.3.366
73. F.X.Vollenweider,, and M.A.Geyer. 2001. A systems model of altered consciousness: Integrating natural and drug-induced psychoses. Brain Research Bulletin 56 (5):495–507. doi:10.1016/S0361-9230(01)00646-3.
74. K.Wolff,, and A.R.Winstock. 2006. Ketamine: From medicine to misuse. CNS Drugs 20 (3):199–218. doi:10.2165/00023210-200620030-00003.
75. C.A.J.Zarate, C. A. Jr., N.E.Brutsche, L.Ibrahim, J.Franco-Chaves, N.Diazgranados, A.Cravchik, J.Selter, C.A.Marquardt, V.Liberty, and D.A.Luckenbaugh. 2012. Replication of ketamine’s antidepressant efficacy in bipolar depression: A randomized controlled add-on trial. Biological Psychiatry 71 (11):939–46. doi:10.1016/j.biopsych.2011.12.010.
76. C.A.J.Zarate, C. A. Jr., J.B.Singh, P.J.Carlson, N.E.Brutsche, R.Ameli, D.A.Luckenbaugh, D.S.Charney, and H.K.Manji. 2006. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Archives of General Psychiatry 63 (8):856–64. doi:10.1001/archpsyc.63.8.856.
77. W.Zhou,, N.Wang, C.Yang, X.-M.Li, Z.-Q.Zhou, and -J.-J.Yang. 2014. Ketamine-induced antidepressant effects are associated with AMPA receptors: Mediated upregulation of mTOR and BDNF in rat hippocampus and prefrontal cortex. European Psychiatry 29 (7):419–23. doi:10.1016/j.eurpsy.2013.10.005.
78. C.F.Zorumski,, S.Mennerick, and Y.Izumi. 2014. Acute and chronic effects of ethanol on learning-related synaptic plasticity. Alcohol 48 (1):1–17. doi:10.1016/j.alcohol.2013.09.045.